|
|
||||||||
The assumed metabolic breakdown of albendazole by mucosal CYP3A4 enzymes was studied by coadministering albendazole (10 mg/kg) with grapefruit juice. Concentrations of albendazole sulfoxide (ABZSX), the active metabolite of albendazole, were compared with those after albendazole was administered with water, a fatty meal, or grapefruit juice plus cimetidine (10 mg/kg). In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031). When grapefruit juice was combined with cimetidine, Cmax was significantly lower than with grapefruit juice alone (0.41 +/- 0.29 mg/l and 0.76 +/- 0.37 mg/l, respectively; P = 0.022). The area under the concentration-time curve from 0 to infinity (AUC(0-omega)) followed a comparable pattern. Half-life (T(1/2)) was 8.8 +/- 4.2 hr and 8.2 +/- 4.3 hr after administration with water or a fatty meal (P = 1.000). Grapefruit juice shortened T(1/2) by 46% (P = 0.026). We hypothesize that albendazole is metabolized by CYP3A4 enzymes in the intestinal mucosa. This process can be inhibited by grapefruit juice. Cimetidine decreased albendazole bioavailability.
This article has been cited by other articles:
![]() |
G. W. AMSDEN, T. B. GREGORY, C. A. MICHALAK, P. GLUE, and C. A. KNIRSCH PHARMACOKINETICS OF AZITHROMYCIN AND THE COMBINATION OF IVERMECTIN AND ALBENDAZOLE WHEN ADMINISTERED ALONE AND CONCURRENTLY IN HEALTHY VOLUNTEERS Am J Trop Med Hyg, June 1, 2007; 76(6): 1153 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. U. Mertens-Talcott, I. Zadezensky, W. V. De Castro, H. Derendorf, and V. Butterweck Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol., December 1, 2006; 46(12): 1390 - 1416. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. OPATRNY, R. PRICHARD, L. SNELL, and J. D. MACLEAN DEATH RELATED TO ALBENDAZOLE-INDUCED PANCYTOPENIA: CASE REPORT AND REVIEW Am J Trop Med Hyg, March 1, 2005; 72(3): 291 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Rigter, H. G. Schipper, R. P. Koopmans, H. J. M. van Kan, H. W. Frijlink, P. A. Kager, and H.-J. Guchelaar Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Crossover Study with Healthy Volunteers Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1051 - 1054. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |